No demonstrable association between the Leningrad–Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt  by Sharma, H.J. et al.
No demonstrable association between the Leningrad–Zagreb mumps
vaccine strain and aseptic meningitis in a large clinical trial in Egypt
H. J. Sharma1, S. Aly Oun2, S. S. Abou Bakr2, S. V. Kapre1, S. S. Jadhav1, R. M. Dhere1 and S. Bhardwaj1*
1) Serum Institute of India Ltd., Pune, India and 2) Ministry of Health & Population, Preventive Sector, Cairo, Egypt
Abstract
To address the claim that the Leningrad–Zagreb (L-Z) mumps vaccine strain is causally associated with aseptic meningitis, a prospective,
post-marketing safety study was conducted with a measles-mumps-rubella vaccine (MMR) (TRESIVAC; Serum Institute of India Ltd.,
Pune, India), which uses the L-Z strain as its mumps component in Egypt. In all, 453 119 children (65 423 children aged 16–24 months
and 329 211 children aged 5–7 years) received MMR. The control groups which, as a result of local health regulations, were slightly
younger than vaccinees, comprised 12 253 and 46 232 children, respectively. Using questionnaires, the parents recorded solicited local,
systemic and neurological adverse events for up to 42 days post-vaccination. All data were analysed externally on an intention-to-treat
basis by individuals not participating in the study. Local and/or systemic reactions were reported in a small percentage of participants,
with pain, fever and parotitis being the most common signs among vaccinees in both age groups. No case of aseptic meningitis, encepha-
litis, anaphylaxis or convulsions was observed in any participant. Thus, in this series of more than 450 000 Egyptian children, the L-Z
mumps vaccine strain in this vaccine did not cause aseptic meningitis. The vaccine is considerably cheaper than Western competitors
and a valid alternative to other MMR vaccines.
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Introduction
Immunization against measles, mumps and rubella is normally
carried out using a combined live virus measles-rubella (MR)
or measles-mumps-rubella (MMR) vaccine. However, ques-
tions have been raised regarding the safety and effectiveness
of the different mumps components. One strain may be safe
and immunogenic but not sufficiently protective [1–3],
whereas another can be very effective but may have a poten-
tial to cause aseptic meningitis [3–6]. Around ten mumps vac-
cine strains have been developed of which Jeryl-Lynn, RIT
4385, Leningrad–Zagreb (L-Z) and Urabe are the best known.
An Indian manufacturer, Serum Institute of India Ltd
(Pune, India), has developed its own MMR vaccine (TRESI-
VAC) in which the L-Z strain is used for mumps protec-
tion. The vaccine was licensed in 1993, and is prequalified by
the WHO. More than 150 million doses have been used in
different countries across five continents.
The experience with this vaccine was positive until three
studies [7–9] from Brazil dealing with a local mass vaccina-
tion campaign raised some doubts over its safety. Estimates
from retrospective analyses in India [10] and Bahamas [11]
suggested that one case of aseptic meningitis is causally asso-
ciated with 57 000–100 000 doses of the L-Z strain. How-
ever, the Brazilian study [7] calculated a rate of one case per
6200–19 000 vaccine doses. Several factors discussed else-
where [12] may explain such discrepancy but, subsequently,
the Indian vaccine has been regarded as possibly less safe
than other MMR vaccines. The Western competitors are
considerably more expensive, and so the prevention of
mumps has often been neglected in poorer countries
because MMR has been ‘replaced’ by MR or even monova-
lent measles vaccine.
To clarify the question of the incidence of the post-L-Z
strain aseptic meningitis [5–7], we conducted a large pro-
spective study in Egypt where MMR could be incorporated
in the existing vaccination programme.
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Materials and Methods
Set-up
Under the auspices of the Ministry of Health and Popula-
tion, Egypt, two open phase IV studies were carried out in
2002–2004. The objective was to assess adverse events
with the Indian-made MMR vaccine (TRESIVAC) in two
paediatric age groups, paying special attention to aseptic
meningitis. Because Egyptian law mandates compulsory
MMR vaccination at age 18–24 months and 6–7 years, the
best feasible control groups comprised children aged 16–
17 months and 5–6 years, respectively. Once the follow-up
ended, these children also received MMR vaccine. Because
the scheduled paediatric immunizations are compulsory in
Egypt, most children received DPT and Hib vaccines during
the study period.
The two age groups involved comprised younger children
aged 16–24 months in nine governerates, and older children
aged 5–7 years in eight governerates of the country. The
study protocol was approved by the Steering Committee on
Vaccines (ethical committee) and consent in writing or by
thumb impression was obtained from a legal guardian. The
study was conducted in accordance with the Declaration of
Helsinki, good clinical practice guidelines, and local regulatory
requirements.
A child of either gender was included in the study if he or
she was healthy, of appropriate age, available for the entire
follow-up period (see below) and consent was obtained. The
exclusion criteria comprised any acute infectious disease, feb-
rile seizures, previous cerebral injury, history of anaphylaxis,
hypersensitivity, anti-cancer medication, radiotherapy, hae-
mophilia or known thrombocytopaenia.
Vaccination
One dose of 0.5 mL of MMR (TRESIVAC) was adminis-
tered subcutaneously in the antero-lateral aspect of the thigh
(young children) or in the deltoid region (school children).
Each dose contained at least 1000 CCID50 of live attenuated
measles viruses of the Edmonston–Zagreb strain propagated
on human diploid cell culture. A dose of the mumps compo-
nent had at least 5000 CCID50 of the L-Z strain propagated
on chick fibroblast cell culture. For rubella, the amount of
the Wistar RA 27/3 strain was at least 1000 CCID50, propa-
gated on human diploid cell culture. Other ingredients were
2.5% of (partially hydrolyzed) gelatin, 5% of sorbitol, and
residual (£15 lg) of neomycin. The diluent was water. A
concomitant vaccination was allowed, if needed.
Twenty-four different lots of the vaccine (EU 615V, EU
618V to EU 640V) were used, all released by National Con-
trol Authority, India, and National Organization for Drug
Control and Research, Egypt.
Collection of data
Bilingual questionnaires (Fig. 1) were used to collect informa-
tion in writing. If the parents were illiterate, a person who
was able to write was asked for help. The solicited adverse
events were classified as local, systemic or neurological
events. The local reactions were pain, swelling or redness at
injection site. For systemic reactions, we specifically asked
for fever measured by thermometer (given to all) from the
axilla in young children and orally from school children, paro-
titis, rash, cervical or axillary lymphadenopathy, or arthralgia.
Because the neurological manifestations were our special
interest, all suspected cases of encephalopathy or encephali-
tis, or any type of meningitis, were to be reported. Parents
were advised of the suggestive symptoms and signs by the
vaccinating physician. The questionnaires (Fig. 1) had an extra
space for potential unlisted events. For serious adverse
events, a special form was used. This was completed by the
principal investigator who was informed within 24 h by e-
mail, fax, or telephone.
In light of the existing information on MMR vaccines
[13,14], reactions were checked by parents for 6 weeks post-
vaccination, divided into days 0, 2, 7–14, 15–28 and 29–42.
Because aseptic meningitis develops within 6 weeks [6], usually
2–3 weeks post-vaccination, the follow-up lasted for 42 days.
When needed, the parents’ information was augmented by the
vaccinating physicians during a visit to hospital or the staff visits
to home. The Adverse Events Following Immunization surveil-
lance system, organized by WHO Expanded Programme on
Immunization, was utilized. School doctors contributed to the
follow-up of the older children.
Analysis of data, and statistical methods
The case report forms were in duplicate, with a copy being
submitted to an external data analyser (iGATE Clinical
Research International, now DiagnoSearch Life Sciences Pvt.
Ltd., Mumbai, India). The severity of adverse events was
scored from 0 (no reaction) to 3 (severe).
For all events, the dates of immunization, onset of event,
resolution of event and the outcome were recorded. Investi-
gators assessed the possible causal relationship to vaccination
as not related, unlikely, suspiciously or probably related. In
addition, reasons for drop-out from the study were
recorded.
Statistical analysis was performed using SAS, version 8.2
(SAS Institute, Cary, NC, USA). Quantitative analysis
included the number, mean, standard deviation, and the
range of the findings, whereas qualitative analysis included
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the number and the percentage of events, and 95% CI where
applicable.
The incidence of adverse events were compared between
the test and control groups using the ‘two sample test for pro-
portion’ [15]. The hypothesis for incidence of events among
vaccinees was tested using the ‘one sample test for proportion’
[15] by formulating null and alternative hypotheses as per
the maximum percentages quoted in the literature as: fever
£15% [14], rash £5% [16], parotitis £1.6% [17], meningitis
£0.11% [18], encephalitis £0.00004% [19], thrombocytopaenia
£0.0033% [20] and arthralgia £0.0003% [21].
Randomly selected vaccination sites and the case record
forms were audited periodically by an external agent (Wider-
perspectives Ltd, Reading, UK). In addition, the study was
monitored by the sponsor’s clinical trial monitors in associa-
tion with doctors from the Ministry of Health and Popula-
tion, Egypt.
Results
Data were obtained from 453 119 children (Fig. 2). Inten-
tion-to-treat analysis comprised 77 676 younger children
(16–24 months) of whom 65 423 were vaccinees and 12 253
were controls. Of the 375 443 older children (5–7 years),
329 211 were vaccinees and 46 232 were controls.
In per-protocol analysis, the corresponding numbers for
the younger children were 73 745 (total) of whom 61 895
were vaccinees and 11 850 were controls. Of the 371 184
older children, 325 204 were vaccinees and 45 980 were con-
trols. There were no drop-outs as a result of adverse events.
Table 1 shows the results of intention-to-treat analysis. The
per-protocol analysis did not differ significantly in any respect.
Younger children
The results of vaccinees vs. controls are listed in Table 2.
Among the 16–24 month old vaccinees, the only adverse
events exceeding a frequency of 1% were fever (2.5% vs.
1.6% in non-MMR vaccinees, p <0.0001), local pain (2.3% vs.
0.08%, p <0.0001) and local redness (1.7% vs. 0.08%,
p <0.0001). Parotitis was very rare and less frequent in vacci-
nees (0.04%) than nonvaccinees (0.17%; p <0.0001).
The local events usually occurred on days 0–3, post-vacci-
nation. No child in either group was reported as developing
meningitis or encephalitis, or with signs or symptoms sug-
gesting involvement of the central nervous system.
FIG. 1. The data were collected with bilingual questionnaires, specifically designed for the study.
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Older children
There were also few adverse events in the 5–7 years age
group (Table 2). The adverse events exceeding 1% in fre-
quency were fever (2.5% vs. 2.9% in non-MMR vaccinees,
p 0.0001), parotitis (2.5% vs. 0.9%, p 0.0001), local pain
(1.32% vs. 0%, p 0.0001) and local redness (1.1% vs. 0%,
p 0.0001).
Local pain was understandably at its highest on day 0
(59%), whereas fever usually rose during days 15–28 post-
vaccination. The median time for onset of parotitis was
18 days. Once parotitis developed, the median resolution
time was 8.4 days.
No child in this group either was reported to have symp-
toms or signs suggesting aseptic meningitis or encephalitis.
One case of Haemophilus influenzae type b meningitis was
detected in a 6.7-year-old girl on day 19 post-vaccination,
although no causal association to vaccination was found.
Ninety-three cases of clinical mumps were observed
among vaccinees (0.03%) vs. 29 cases (0.06%) in controls.
Measles was diagnosed clinically in four vaccinees and three
controls. A causal association with MMR vaccination was
unlikely.
Discussion
The central finding of the present study was that no aseptic
meningitis or other involvement of the central nervous sys-
tem was detected in a series of 394 634 vaccinated Egyptian
children aged 18–24 months or 6–7 years. The finding
Children 5–7 years 
Assessed for eligibility = 37 5477 
Study vaccine 
group = 329 211 
Unvaccinated control 
group = 46 232 
Lost to follow up = 
4007
Lost to follow up =
252
No. of subjects for 
ATP cohort
= 325 204 
No. of subjects for 
ATP cohort
= 45 980 
Children 16–24 months 
Assessed for eligibility = 77 691 
Missing data =15 
Study vaccine group 
= 65 423 
Unvaccinated control 
group = 12 253 
Lost to follow up = 
3528
Lost to follow up = 
403
No. of subjects for 
ATP cohort
= 61 895 
No. of subjects for 
ATP cohort
= 11 850 
ITT cohort = 77 676 
Missing data = 34 
ITT cohort = 37 5443
FIG. 2. Trial profile. ATP, according to
protocol; ITT, intention-to-treat.
TABLE 1. Demographic character-
istics of the vaccinees vs. nonvacci-
nees, intention-to-treat analysisParameter
16–24 months 5–7 years
Study group Control group Study group Control group
Number (n) 65 423 12 253 329 211 46 232
Age (mean ± SD) 18.66 ± 0.98 16.75 ± 0.72 6.46 ± 0.31 5.42 ± 0.26
Sex
Male 33 504 6399 166 180 24 621
Female 30 990 5745 160 281 21 191
Unknowna 929 109 2750 420
aAllocated to study or control group, but gender not defined.
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supports the view, held prior to the Brazilian reports [7–9],
that the Indian MMR vaccine is a safe product. Our data sup-
port an earlier study suggesting that the risk of aseptic men-
ingitis following the use of the L-Z strain is 0.9 cases per
100 000 doses [10]. These figures place the L-Z strain in the
same category as the Jeryl-Lynn strain with one case per
800 000 doses [22]. These two strains are considerably safer
than the Leningrad-3 or the Urabe strains, which cause asep-
tic meningitis once per 1000 doses [23] or up to 900 doses
[24], respectively.
It may not always be in the interests of the community to
use the vaccine that is deemed the safest [25]. In its position
paper [23], the WHO rightly states that, in mumps vaccina-
tion, strain-specific differences in adverse events exist but
are not strong enough to form the basis of a recommenda-
tion; all current strains except Rubini are valid alternatives.
Now that even the Jeryl-Lynn strain has failed [26], we think
it is time to reconsider the value of all potential vaccine
strains [3]. The low price of Indian MMR vaccine adds to its
value in a large scale use. It should also be kept in mind that
the ‘same’ strain used by different manufacturers might have
changed over the years. This view is supported by the great
variation in the reported incidence of post-L-Z aseptic men-
ingitis: from one case per 900 doses (one prefecture in
Japan) [24] through 1:62 000 (Canada) [27] up to 1:120 000
(France) [28].
Although convinced of the safety of the Indian vaccine, we
are aware of limitations with respect to the present study. It
was not double-blind, but open, and thus prone to errors in
reporting. However, a double-blind study large enough to
detect very rare cases of aseptic meningitis in rural Egypt
would have required insurmountable resources. The control
groups were not ideal because the ages were slightly dissimilar;
this selection had to be made to fit with the legal vaccination
requirements of Egypt. The adverse events were not checked
daily, although, optimally, they should have been [14,29].
Instead, the checking was grouped in pre-set time periods and
even this was not easy to achieve. Finally, the vaccinees had
been immunized against measles at age 9 months (a legal
requirement). This undoubtly reduced the reactions (such as
fever) but is highly unlikely to have affected our main outcome
variable: aseptic meningitis associating with the L-Z strain.
Therefore, despite these limitations, we believe that valu-
able information was obtained from this very large
(n > 450 000) study. The L-Z mumps vaccine strain was not
found to be associated with aseptic meningitis. Because the
Indian-made measles and rubella components have shown
good safety and effectiveness, this MMR combination poses
an appropriate and inexpensive alternative to the widely used
Western competitors.
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